63 related articles for article (PubMed ID: 24022727)
1. KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond.
Malapelle U; Carlomagno C; de Luca C; Bellevicine C; Troncone G
J Clin Pathol; 2014 Jan; 67(1):1-9. PubMed ID: 24022727
[TBL] [Abstract][Full Text] [Related]
2. Clinical implementation of KRAS testing in metastatic colorectal carcinoma: the pathologist's perspective.
Ross JS
Arch Pathol Lab Med; 2012 Oct; 136(10):1298-307. PubMed ID: 22272560
[TBL] [Abstract][Full Text] [Related]
3. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.
Krol LC; 't Hart NA; Methorst N; Knol AJ; Prinsen C; Boers JE
Eur J Cancer; 2012 May; 48(7):1108-15. PubMed ID: 22446020
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
5. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
Prenen H; Tejpar S; Van Cutsem E
Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
[TBL] [Abstract][Full Text] [Related]
7. KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.
Normanno N; Pinto C; Castiglione F; Bardelli A; Gambacorta M; Botti G; Nappi O; Siena S; Ciardiello F; Taddei G; Marchetti A
PLoS One; 2011; 6(12):e29146. PubMed ID: 22216189
[TBL] [Abstract][Full Text] [Related]
8. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.
Berg M; Soreide K
Discov Med; 2012 Sep; 14(76):207-14. PubMed ID: 23021375
[TBL] [Abstract][Full Text] [Related]
9. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
[TBL] [Abstract][Full Text] [Related]
10. Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer.
Aubin F; Gill S; Burkes R; Colwell B; Kamel-Reid S; Koski S; Pollett A; Samson B; Tehfe M; Wong R; Young S; Soulières D
Curr Oncol; 2011 Aug; 18(4):e180-4. PubMed ID: 21874108
[TBL] [Abstract][Full Text] [Related]
11. How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.
Richman SD; Fairley J; Butler R; Deans ZC
J Clin Pathol; 2017 Jan; 70(1):58-62. PubMed ID: 27681846
[TBL] [Abstract][Full Text] [Related]
12. The ideal reporting of
Malapelle U; Angerilli V; Pepe F; Fontanini G; Lonardi S; Scartozzi M; Memeo L; Pruneri G; Marchetti A; Perrone G; Fassan M
Pathologica; 2023 Jun; 115(3):137-47. PubMed ID: 37314870
[No Abstract] [Full Text] [Related]
13. Molecular markers in cervical cytology.
Altiok S
Clin Lab Med; 2003 Sep; 23(3):709-28, vii. PubMed ID: 14560536
[TBL] [Abstract][Full Text] [Related]
14. Laboratory Genetic Testing in Clinical Practice 2016.
Cogulu O; Schoumans J; Toruner G; Demkow U; Karaca E; Durmaz AA
Biomed Res Int; 2017; 2017():5798714. PubMed ID: 28133609
[No Abstract] [Full Text] [Related]
15. Clonal evolution and
Sartore-Bianchi A; Valtorta E; Amatu A; Veronese S; Lauricella C; Bonazzina E; Siravegna G; Truini M; Bardelli A; Siena S
ESMO Open; 2016; 1(4):e000079. PubMed ID: 27843629
[No Abstract] [Full Text] [Related]
16. Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?
Mileshkin L; Shah B; Michael M
Chemother Res Pract; 2012; 2012():838509. PubMed ID: 22666589
[TBL] [Abstract][Full Text] [Related]
17. KRAS Testing: Optimizing Cancer Therapy.
Carlson B
Biotechnol Healthc; 2009; 6(5):7-9. PubMed ID: 22478793
[No Abstract] [Full Text] [Related]
18. Clinical relevance of KRAS mutations in codon 13: Where are we?
Er TK; Chen CC; Bujanda L; Herreros-Villanueva M
Cancer Lett; 2014 Feb; 343(1):1-5. PubMed ID: 24051306
[TBL] [Abstract][Full Text] [Related]
19. Management of colorectal cancer.
Stintzing S
F1000Prime Rep; 2014; 6():108. PubMed ID: 25580262
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
Kirstein MM; Lange A; Prenzler A; Manns MP; Kubicka S; Vogel A
Oncologist; 2014 Nov; 19(11):1156-68. PubMed ID: 25326159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
